Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 932-051-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 6 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 149.9 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- There is no reliable repeated dose inhalation data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. There are no exact absorption factors for oral and inhalative resorpiton available, therefore in conclusion it is expected that the absoption factors for both routes are 100 %. That means an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- Exposure duration (subchronic study)
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not typically applied in the derivation of an inhalation DNEL.
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- worker
- AF for the quality of the whole database:
- 1
- Justification:
- good qualitiy
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 85 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 8 500 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- For long-term, worker, dermal exposures, the DNEL is derived using the oral NOAEL of the repeated dose study on LAS as the starting point. This oral NOAEL starting point value must then be corrected for route-to-route extrapolation for the dermal route. A study on LAS is used as starting point, therefore also the dermal absorption factor of LAS is used for calculating the dermal NOAEL. In this case it is more reasonable to use the LAS dermal factor and not the dermal absorption factor of hydrotropes because this study is the base of the calculation. Based on data from a dermal absorption study of a C12 LAS homologue in isolated human epidermis (Howes 1975) that indicated < 0.065% of the applied dose penetrated the skin in 48 hours, 1% dermal absorption is conservatively assumed. The dermal NOAEL is therefore 8500 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- eposure duration (subchronic to chronic)
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- worker
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- high hazard (no threshold derived)
Additional information - workers
There are no repeat dose studies with Marlon ARL, however, there are such studies for the major constituent (i.e., LAS). The acute toxicity of Marlon ARL and LAS are comparable, oral LD50s of 2240 and 1080 mg/kg respectively, and dermal LD50s of 2000 for each of the substances. LAS is therefore used as a read across substance, and the DNELs for long term exposure to workers and the general population are based on the highest NOAEL below the lowest LOAEL in repeated dose studies; 85 mg/kg bw/day (Yoneyama et al, 1976) in a 9-month exposure (systemic effects).
Yoneyama, M et al, 1976. Subacute toxicity of linear alkylbenzene sulfonate cited in IPCS. 1996. Environmental Health Criteria 169. LAS and related compounds. World Health Organization, Geneva, Switzerland.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.5 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 79.3 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- There is no reliable repeated dose inhalation data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. There are no exact absorption factors for oral and inhalative resorpiton available, therefore in conclusion it is expected that the absoption factors for both routes are 100 %. That means an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- Exposure duration (subchronic study)
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not typically applied in the derivation of an inhalation DNEL.
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- worker
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 42.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 8 500 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- For long-term, General Population, dermal exposures, the DNEL is derived using the oral NOAEL of the repeated dose study on LAS as the starting point. This oral NOAEL starting point value must then be corrected for route-to-route extrapolation for the dermal route. A study on LAS is used as starting point, therefore also the dermal absorption factor of LAS is used for calculating the dermal NOAEL. In this case it is more reasonable to use the LAS dermal factor and not the dermal absorption factor of hydrotropes because this study is the base of the calculation. Based on data from a dermal absorption study of a C12 LAS homologue in isolated human epidermis (Howes 1975) that indicated < 0.065% of the applied dose penetrated the skin in 48 hours, 1% dermal absorption is conservatively assumed. The dermal NOAEL is therefore 8500 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- Exposure duration (subchronic study)
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- general population
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.425 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 85 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- not route-to-route
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- Exposure duration (subchronic study)
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- general population
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- high hazard (no threshold derived)
Additional information - General Population
There are no repeat dose studies with Marlon ARL, however, there are such studies for the major constituent (i.e., LAS). The acute toxicity of Marlon ARL and LAS are comparable, oral LD50s of 2240 and 1080 mg/kg respectively, and dermal LD50s of 2000 for each of the substances. LAS is therefore used as a read across substance, and the DNELs for long term exposure to workers and the general population are based on the highest NOAEL below the lowest LOAEL in chronic studies; 85 mg/kg bw/day (Yoneyama et al, 1976) in a 9-month exposure (systemic effects).
Yoneyama, M et al, 1976. Subacute toxicity of linear alkylbenzene sulfonate cited in IPCS. 1996. Environmental Health Criteria 169. LAS and related compounds. World Health Organization, Geneva, Switzerland.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.